|
|
News Breaks | | | | April 20, 2012 | | 10:45 EDT |  | MJN, PFE, NSRGY, DANOY | Danone raised offer to near $11B for Pfizer unit, Reuters reports
Danone (DANOY) raised its offer for Pfizer's (PFE) infant nutrition business to close to $11B in an attempt to outbid Nestle (NSRGY), according to news website WanSquare, Reuters reports. Nestle was expected to close on a deal to buy the Pfizer unit for up to $10B, according to sources, Reuters added. Reference Link | |
|
News For PFE;DANOY;NSRGY;MJN From The Last 14 Days Check below for free stories on PFE;DANOY;NSRGY;MJN the last two weeks. |
|
|
| May 21, 2013 | | 07:16 EDT |  | PFE | Pfizer management to meet with Leerink
 Subscribe for More Information | | | May 20, 2013 | | 17:04 EDT |  | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information | | | 07:13 EDT | | DANOY | Danone to invest $417M in deals with China Mengniu Dairy, Reuters reports
Danone Group will invest $417M in two deals with China Mengniu Dairy Co., marking a comeback for the French group in China where scandals have hurt confidence in food safety, reports Reuters.Reference Link | | | 06:09 EDT | | DANOY | On the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: The New York Department of Financial Services yesterday sent subpoenas to Apollo Global Management (APO), Guggenheim Partners and Harbinger Group (HRG) as part of an investigation seeking more information on investments that back so-called fixed annuities, sources say, the Wall Street Journal reports...As Home Depot (HD) and Lowe’s (LOW) report fiscal Q1 results this week, the reconstruction phase from last year's superstorm Sandy will be looming large as cooler-than-normal temperatures delay spring selling, the Wall Street Journal reports...REUTERS: Danone Group (DANOY) will invest $417M in two deals with China Mengniu Dairy Co., marking a comeback for the French group in China where scandals have hurt confidence in food safety, Reuters reports...The Nikkei share average surged to a new 5 1/2 year high today, boosted by further weakness in the yen and optimism over the growth outlook after the Japanese government raised its assessment of the economy for the first time in two months, Reuters reports...BLOOMBERG: The longest decline in Treasuries this year has left U.S. government debt the cheapest since March 2011 when measured by real yields and the best relative value compared with German bunds in more than two decades, Bloomberg reports...As JPMorgan Chase’s (JPM) Jamie Dimon prepares for a vote Tuesday on whether he should keep his chairman and CEO titles, he may take comfort knowing that seven of the bank’s 10 largest owners are run by CEOs who are also chairmen, Bloomberg reports. | | | May 16, 2013 | | 09:27 EDT | | NSRGY | Nestle invests CHF 29M to strengthen supply chain in Russia
Nestlé is investing more than CHF 29M in new distribution facilities in Russia to meet growing demand for its products in the country. The company is extending its distribution centre at its manufacturing site in Vorsino in the region of Kaluga to better serve consumers across Russia and other Commonwealth of Independent States countries. The investment will have created about 100 new jobs by the time the new facilities are fully operational in October this year. | | | 08:55 EDT | | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information | | | May 14, 2013 | | 17:48 EDT | | MJN | Lone Pine gives quarterly update on stakes
NEW STAKES: Valeant Pharmaceuticals (VRX), Virgin Media (VMED), Thermo Fisher Scientific (TMO), CME Group (CME), and Liberty Media (LMCA). INCREASED STAKES: Mead Johnson Nutrition (MJN), News Corp (NWSA), Intuitive Surgical (ISRG), Monsanto (MON), and Qualcomm (QCOM). DECREASED STAKES: Cognizant Technology Solutions (CTSH), Equinix (EQIX), Ralph Lauren (RL), Disney (DIS), and Oceaneering International (OII). LIQUIDATED STAKES: Facebook (FB), Crown Castle (CCI), Accretive Health (AH), Informatica (INFA), and NetEase (NTES). | | | May 13, 2013 | | 07:10 EDT | | NSRGY | Companies pursue more deals in India, Bloomberg reports
The largest overseas bet on Indian consumers is spurring speculation that companies from Nestle (NSRGY) to Colgate-Palmolive (CL) will pursue more deals in a nation where household income is forecast to triple this decade, reports Bloomberg.Reference Link | | | 06:05 EDT | | NSRGY | On the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: U.S. companies are on track to raise the most money through IPOs since before the financial crisis, driven by the same thirst for risk among investors that has pushed the stock market to new highs. Already this year, 64 U.S.-listed public offerings have raised $16.8B, according to Dealogic, the Wall Street Journal reports...Cisco Systems (CSCO) shares fell this time last year after executives warned their biggest corporate customers were ordering less equipment. If history repeats itself this week, the networking giant will join a dreary but growing club (IBM, JNPR), the Wall Street Journal reports...REUTERS: Japan's Nikkei share average surged to a new 5-1/2-year high today as the weakening yen further bolstered exporters, while brokerage shares attracted buyers who see growing volume bringing in much more fee income, Reuters reports...China's factory output growth was surprisingly muted in April, darkening the outlook for the Chinese economic recovery and feeding expectations that the government may take policy action to support activity. Annual industrial output grew 9.3%, up from 8.9% in March but still missing market expectations for a 9.5%, Reuters reports...BLOOMBERG: Wall Street’s major bond dealers are beginning to forecast that the Treasury Department will lower the size of its debt auctions in coming months for the first time in three years as government revenue soars, Bloomberg reports...The largest overseas bet on Indian consumers is spurring speculation that companies from Nestle (NSRGY) to Colgate-Palmolive (CL) will pursue more deals in a nation where household income is forecast to triple this decade, Bloomberg reports. | | | May 10, 2013 | | 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information | | | | 12:31 EDT | | PFE | On The Fly: Midday Wrap
Subscribe for More Information | | | 11:48 EDT | | PFE | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | 09:21 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information | | | 08:08 EDT | | PFE | Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. | | | 07:46 EDT | | PFE | DURECT says additional clinical studies needed for Remoxy
DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. | | | May 9, 2013 | | 10:17 EDT | | PFE | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information | | | May 8, 2013 | | 10:33 EDT | | PFE | Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis
Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. | |
|
|
|
|
|
|
